A Diagnostic Workflow for Weak and Multiple Instruments

Why an IV Analysis Needs a Workflow

With multiple instruments, a collection of individually plausible diagnostics can still leave important questions unanswered. A large first-stage statistic does not establish that the instruments are valid; a non-significant overidentification test does not prove validity; and a conventional two-stage least-squares confidence interval can be misleading when instruments are weak. A useful analysis therefore makes the model and its assumptions explicit, checks relevance, uses inference appropriate to the observed strength, and reports limitations that diagnostics cannot resolve.

The workflow here concerns one endogenous treatment and a linear outcome model, possibly with included exogenous controls. It brings together established results on weak-instrument inference, overidentifying restrictions, many-instrument behavior, and heterogeneous effects. These steps guide interpretation; they do not turn statistical tests into proof of causal assumptions.

Model and Conditions to Keep in View

Definition: Let $Y_i$ be an outcome, $D_i$ an endogenous treatment, $Z_i$ a vector of $q$ excluded instruments, and $X_i$ a vector of included exogenous controls. A linear IV model writes $$ Y_i = \beta D_i + X_i'\gamma + u_i, $$ with a first stage $$ D_i = Z_i'\pi + X_i'\delta + v_i. $$ Here $\beta$ is the coefficient of interest. The instruments must be relevant for $D_i$ conditional on $X_i$, and valid for the causal interpretation: conditional on $X_i$, they must be independent of the outcome disturbance and affect $Y_i$ only through $D_i$. The model also requires an appropriate sampling and error structure for the particular estimation and inference procedure.

These conditions have different roles. Relevance is partly assessable from observed data: the excluded instruments must predict treatment after accounting for the controls. Independence and exclusion are substantive assumptions; a first-stage statistic cannot establish them. With multiple instruments, the rank condition requires enough independent variation in the excluded instruments to identify the endogenous treatment. Inference also depends on using standard errors and test procedures appropriate to the design, including clustering when observations are clustered.

The central practical distinction is between identification and strength of identification. An instrument set may satisfy a population rank condition while providing little sample information about $\beta$. In that setting, conventional approximations can perform poorly even though the model is formally identified.

Step 1: Assess Conditional First-Stage Strength

Estimate the first stage with the same controls and sample used in the outcome analysis. The excluded-instrument test asks whether the coefficients on $Z_i$ are jointly zero after conditioning on $X_i$. In a classical homoskedastic linear model, the partial $F$ statistic compares the restricted model, which includes $X_i$ but excludes $Z_i$, with the unrestricted first stage. With heteroskedasticity or clustering, use a corresponding robust joint test rather than an ordinary homoskedastic $F$ statistic.

A small first-stage $p$-value is evidence against a zero first stage, but it is not a guarantee of adequate strength. Strength depends on the magnitude and precision of the conditional first-stage relationship, the number of instruments, the sample design, and the inferential goal. Stock–Yogo critical values address particular settings and criteria; they are not universal cutoffs for every estimator or design. Report the statistic, its reference distribution or robust test method, and the context needed to interpret it.

Worked Example: A Significant First Stage That Still Raises Concern

Suppose a hypothetical study has $n=600$ observations, one treatment, two excluded instruments, and the same prespecified controls in both stages. In the first stage, the two instrument coefficients are $0.08$ and $0.07$, each with standard error $0.04$. For illustration, suppose their estimated covariance is zero and the classical partial $F$ test is appropriate.

The joint Wald statistic for the two coefficients is $$ F = \frac{1}{2}\left[\left(\frac{0.08}{0.04}\right)^2+\left(\frac{0.07}{0.04}\right)^2\right] = \frac{1}{2}(4+3.0625)=3.531. $$

The reference distribution is approximately $F(2,596)$, giving a $p$-value of about $0.030$. Thus the test rejects the null that both first-stage coefficients are zero at the 5% level. That result is not evidence that the instruments are strong enough for conventional two-stage least-squares inference: the observed joint statistic is modest, so weak-identification-robust inference deserves priority. Nor does the test address independence or exclusion.

Step 2: Use Inference That Is Robust to Weak Identification

When the first stage is weak or its adequacy is uncertain, do not select a conventional confidence interval merely because the first-stage test rejects zero. One option is to invert an Anderson–Rubin (AR) test. For a candidate value $\beta_0$, form the outcome residual under that value, $Y_i-\beta_0D_i$, and test whether the excluded instruments jointly predict it after accounting for $X_i$. Under the null $\beta=\beta_0$, valid instruments, and the relevant sampling assumptions, this test does not rely on a strong first stage. A confidence set contains the candidate values not rejected by the test.

The set may be wide, unbounded, or even disconnected. Those shapes are informative: they can show that the data do not sharply determine the effect. Weak-identification-robust inference protects test size under weak relevance; it does not repair invalid instruments, misspecified controls, or inappropriate standard errors. Other procedures, such as conditional likelihood ratio methods, may also be useful, with their suitability depending on the model and inferential setting.

Worked Example: Inverting a Two-Instrument AR Test

Continue with a hypothetical linear model containing two excluded instruments and one endogenous treatment. Suppose the estimated reduced-form coefficients of the instruments on $Y$ are $(0.12, 0.10)$, and those on $D$ are $(0.08, 0.07)$. To make the calculation transparent, suppose the estimated covariance structure implies that, for each instrument, the variance of its reduced-form coefficient on $Y-\beta D$ is $$ V(\beta)=0.0025+0.0016\beta^2-0.0008\beta, $$ and the two instrument coefficient estimates are uncorrelated with one another. Use a large-sample chi-square reference distribution for the joint AR test, with $q=2$ degrees of freedom.

At a candidate value $\beta_0=1$, the two reduced-form coefficients for $Y-\beta_0D$ are $0.12-0.08=0.04$ and $0.10-0.07=0.03$. The variance is $V(1)=0.0025+0.0016-0.0008=0.0033$, so $$ AR(1)=\frac{0.04^2+0.03^2}{0.0033} =\frac{0.0025}{0.0033}=0.7576. $$ Since $0.7576<\chi^2_{2,0.95}=5.991$, this candidate is not rejected at the 5% level.

To obtain the confidence set, retain all $\beta$ satisfying $$ \frac{(0.12-0.08\beta)^2+(0.10-0.07\beta)^2} {0.0025+0.0016\beta^2-0.0008\beta}\leq 5.991. $$ The denominator is positive for all $\beta$, so multiplying through and collecting terms gives $$ 0.0017144\beta^2-0.0284072\beta+0.0094225\leq 0. $$ The two roots are approximately $0.339$ and $16.2$; because the quadratic opens upward, the 95% AR confidence set is approximately $[0.339,16.2]$. The set is broad: although it includes $\beta=1$, it also includes many substantially larger effects. The calculation illustrates why a weak-first-stage analysis should report the robust set rather than relying only on a conventional interval.

Step 3: Read an Overidentification Test Narrowly

When there are more excluded instruments than endogenous treatments, the model imposes restrictions that can be tested jointly. In the linear, overidentified IV model, the $J$ statistic tests whether the sample moment conditions are jointly compatible with the fitted model. Under the null of valid moment restrictions and appropriate regularity and estimation conditions, its large-sample reference distribution has degrees of freedom equal to the number of overidentifying restrictions: $q$ excluded instruments minus the number of endogenous regressors.

A rejection signals a conflict with at least part of the joint set of restrictions; it does not identify which instrument or assumption is responsible. Failure to reject means only that the test did not detect a conflict at its available power. It does not establish independence or exclusion. In particular, treatment-effect heterogeneity can also affect the interpretation of overidentification tests: instrument-specific estimates may differ because instruments shift treatment for different populations, not only because an instrument is invalid.

Worked Example: Interpreting a Non-Significant J Test

Suppose a hypothetical analysis has one endogenous treatment and three excluded instruments, so there are $3-1=2$ overidentifying restrictions. An estimated $J$ statistic is $1.12$. Under the stated large-sample reference distribution, $$ P(\chi^2_2\geq 1.12)=\exp(-1.12/2)=\exp(-0.56)=0.571. $$

At $\alpha=0.05$, the test does not reject the joint moment restrictions because $1.12<\chi^2_{2,0.95}=5.991$, equivalently because $0.571>0.05$. The defensible conclusion is that this test does not detect a conflict with the joint restrictions at the 5% level. It is not defensible to conclude that all three instruments have been proven valid. A weak test, low power, or offsetting violations can leave important problems undetected.

Step 4: Account for Many Instruments and Heterogeneous Effects

A large instrument count relative to the sample size is a warning about finite-sample behavior, not a universal threshold-based verdict. With many instruments, first-stage fitted treatment can track sample-specific variation closely. Two-stage least squares can then have appreciable finite-sample bias toward the ordinary least-squares estimate, and standard large-sample approximations may be unreliable. Reporting the instrument count, sample size, first-stage diagnostics, estimator, and sensitivity to reasonable alternatives helps readers assess this risk. LIML or Fuller estimation can be useful comparisons in some settings, but changing estimators does not validate instruments or eliminate every weakness.

Instrument count must also be considered alongside the nature of the instrument set. Many weak or redundant instruments can create problems; reducing the set is not automatically a solution, because dropping instruments based on observed results can introduce selection concerns or remove useful variation. A defensible reduction should have a substantive or design-based rationale, and any data-driven choice needs inference that accounts for selection.

Finally, a single linear IV coefficient need not represent one common treatment effect for everyone. Under treatment-effect heterogeneity, instruments can induce different changes in treatment among different groups. Instrument-specific Wald estimates and two-stage least-squares estimates can therefore reflect different local effects or weighted combinations of effects. A discrepancy across instruments may prompt investigation, but it is not by itself a definitive validity test; agreement likewise does not prove a common effect or valid instruments. State the target interpretation justified by the design and assumptions, and avoid presenting an IV coefficient as a universal population effect without support.

Worked Example: Reporting Many-Instrument and Heterogeneity Limitations

Consider a hypothetical sample of $n=120$ with $q=40$ excluded instruments and one endogenous treatment. The instrument-to-observation ratio is $$ \frac{q}{n}=\frac{40}{120}=0.333. $$ Suppose the conventional two-stage least-squares estimate is $0.42$, the LIML estimate is $0.68$, and the Fuller estimate is $0.61$, all in outcome units per one-unit increase in treatment. The spread across these hypothetical estimates is a reason to report estimator sensitivity, not a basis for choosing the largest estimate or declaring one estimator correct. The ratio $0.333$ is descriptive, not a formal cutoff that classifies the design as invalid.

Suppose further that instrument-specific Wald estimates range from $0.30$ to $0.90$ outcome units per treatment unit. Under heterogeneous effects, this spread could reflect differences in the groups whose treatment is shifted by each instrument; it could also reflect weak precision or violations of assumptions. Without additional design information, the numbers do not distinguish these explanations. A careful report would give the instrument count and sample size, the first-stage and weak-robust results, estimator sensitivity, and the plausible local or weighted interpretation of the estimates.

A Compact Diagnostic Workflow

Specify the model and assumptions.
Name the outcome, treatment, excluded instruments, controls, target coefficient, and the relevance, independence, and exclusion conditions required for a causal interpretation.

Check relevance in the analysis sample.
Report the conditional first-stage joint test and use a robust version appropriate to the error structure. Treat strength as a matter of degree, not as a binary conclusion from a single threshold.

Choose inference for the observed strength.
If weak identification is plausible, report a weak-identification-robust confidence set, such as an inverted AR set, and describe its width and shape.

Interpret overidentification tests cautiously.
Report the statistic, degrees of freedom, and $p$-value. Explain that rejection flags a conflict and non-rejection does not prove validity.

Describe complexity and the estimand.
Report the number of instruments relative to the sample, sensitivity to suitable estimators, and how heterogeneous responses may shape the IV effect.

Common Mistake: Treating Diagnostics as a Validity Certificate

A tempting but incorrect summary is: “The first-stage $p$-value is below 0.05, the overidentification test is not significant, so the instruments are strong and valid.” The first test concerns whether the excluded instruments jointly predict treatment under its assumptions; it does not show that the strength is adequate for conventional inference. The overidentification test can fail to detect invalidity, and its interpretation can be affected by heterogeneous effects. Neither test verifies independence or exclusion.

A better report separates what the data test from what the design must justify: show conditional first-stage evidence; use inference robust to weak identification when warranted; give the overidentification result without treating non-rejection as validation; and explain many-instrument and treatment-effect heterogeneity limitations. This keeps statistical diagnostics informative without asking them to answer causal questions they cannot settle.

Key takeaway: A credible IV workflow does not hinge on one diagnostic. Assess conditional relevance, use weak-identification-robust inference when strength is uncertain, interpret overidentification tests narrowly, and report how instrument count and heterogeneous effects limit the meaning of the estimate.

Check Your Understanding

Use the workflow to answer these questions.

Why does rejecting a zero first-stage null not by itself establish that conventional two-stage least-squares inference is reliable?
What does an AR confidence set contain, and why can it be wide or unbounded when instruments are weak?
In an overidentified model, what can a significant $J$ test indicate, and what can a non-significant result not establish?
Why might adding instruments increase finite-sample concerns even if they are individually relevant?
How can treatment-effect heterogeneity complicate comparisons of instrument-specific Wald estimates?